Pneumococcal Type IV Antigen, CRM197-Conjugate_天津卡梅德科技发展有限公司

>>

>>

>>

>

Pneumococcal Type IV Antigen, CRM197-Conjugate

Pneumococcal Type IV Antigen, CRM197-Conjugate

产品编号

BAG1133

别名

CRM197结合4型肺炎球菌抗原,CRM197结合肺炎球菌抗原, 肺炎球菌, Pneumococcal Type IV, CRM197

规格

250ul
1ml

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Catalog Number	BAG1133
Alias	CRM197结合4型肺炎球菌抗原,CRM197结合肺炎球菌抗原, 肺炎球菌, Pneumococcal Type IV, CRM197
Size	250ul, 1ml
Molecular Name	Pneumococcal
Expression System	Pneumococcal
Species	Bacteria
Purity	>95%
Purification	IEC & HPLC
Storage Condition	Store the lyophilized powder at 4℃ for 6 months. It is recommended to aliquote to ~10ul per vial and store at -20℃ for long term storage. Avoid repeated freezing and thawing cycles.
Formulation	Powder or 0.1M PBS, PH 7.0
Background	Pneumococcal pneumonia is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (which is also called pneumococcus). It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900, 000 annually, with almost 400, 000 cases hospitalized and fatalities accounting for 5-7% of these cases.
Application	Immunogen, WB, ELISA

FAQ

为什么选择CRM197作为载体蛋白，而不是其他蛋白（如破伤风类毒素TT或白喉类毒素DT）？

CRM197相较于其他传统载体蛋白有几个显著优势：安全性高：作为天然白喉毒素的无毒突变体，其安全性记录极佳，大规模使用中不良反应率低。免疫原性强：能非常有效地刺激辅助T细胞，产生强大的免疫增强效果。无预存免疫干扰：在婴幼儿中，对白喉毒素/CRM197的预存抗体水平通常很低。相比之下，使用TT或DT作为载体时，母亲传给的抗体或婴儿常规接种的百白破疫苗可能产生预存抗体，理论上可能干扰新结合疫苗的免疫效果。CRM197在一定程度上避免了这种潜在干扰。工艺成熟：其重组生产技术成熟稳定，易于实现大规模、高纯度的生产。

推荐产品

400-621-6806
18630936064（微信同号）
周一至周五 8:30-18:00
0